This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.
Approval for the melafind device. Melafind is intended for use on clinically atypical cutaneous pigmented lesions with one or more clinical or historical characteristics of melanoma, excluding those with a clinical diagnosis of melanoma or likely melanoma. Melafind is designed to be used when a dermatologist chooses to obtain additional information for a decision to biopsy. Melafind should not be used to confirm a clinical diagnosis of melanoma. Melafind is only for use by physicians trained in the clinical diagnosis and management of skin cancer (i. E. , dermatologists) who have also successfully completed a training program in the appropriate use of melafind. The melafind result is one element of the overall clinical assessment. Melafind positive lesions (which may include malignant melanoma, melanoma in situ, high grade dysplastic nevi and atypical melanocytic proliferation/hyper-plasia) should be considered for biopsy; the biopsydecision of a melafind negative lesion should be based on the remainder of the entire clinical context. Lesions that are "non-evaluable" by melafind should be carefully re-evaluated for biopsy. Melafind is indicated only for use on lesions with a diameter between 2 mm and 22 mm, lesions that are accessible by the melafind imager, lesions that are sufficiently pigmented (i. E. Not for use on non-pigmented or skin-colored lesions), lesions that do not contain a scar orfibrosis consistent with previous trauma, lesions where the skin is intact (le. , non-ulcerated or non-bleeding lesions), lesions greater than 1 cm away from the eye, lesions which do not contain foreign matter, and lesions not on special anatomic sites (ie. , not for use on acral,palmar, plantar, mucosal, or subungual areas). Melafind is not designed to detect pigmented non-melanoma skin cancers, so the dermatologist should rely on clinical experience to diagnose such lesions.
| Device | MELAFIND |
| Classification Name | Optical Diagnostic Device For Melanoma Detection |
| Generic Name | Optical Diagnostic Device For Melanoma Detection |
| Applicant | STRATA SKIN SCIENCES, INC. |
| Date Received | 2009-06-03 |
| Decision Date | 2011-11-01 |
| Notice Date | 2012-01-24 |
| PMA | P090012 |
| Supplement | S |
| Product Code | OYD |
| Docket Number | 12M-0074 |
| Advisory Committee | General & Plastic Surgery |
| Expedited Review | Yes |
| Combination Product | No |
| Applicant Address | STRATA SKIN SCIENCES, INC. 100 Lakeside Dr Ste 100 horsham, PA 19044 |
| Summary: | Summary of Safety and Effectiveness |
| Labeling: | Labeling |
| Post-Approval Study: | Show Report Schedule and Study Progress |
| Approval Order: | Approval Order |
| Supplement Number | Date | Supplement Type |
|---|---|---|
| P090012 | Original Filing | |
| S011 | 2015-06-11 | Normal 180 Day Track |
| S010 | 2014-06-17 | Normal 180 Day Track |
| S009 | 2014-04-29 | 30-day Notice |
| S008 | 2014-04-29 | 135 Review Track For 30-day Notice |
| S007 | 2014-04-29 | 135 Review Track For 30-day Notice |
| S006 | 2014-04-29 | 135 Review Track For 30-day Notice |
| S005 | 2014-04-29 | 135 Review Track For 30-day Notice |
| S004 | 2014-04-29 | 135 Review Track For 30-day Notice |
| S003 | 2014-02-12 | Normal 180 Day Track No User Fee |
| S002 | 2012-08-13 | Normal 180 Day Track No User Fee |
| S001 | 2011-11-01 | Normal 180 Day Track No User Fee |